We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products. We currently manufacture and sell over 25 prescription pharmaceutical products, and an over-the-counter product, Primatene MIST ® .
Status note Will target multiple indications per filing.
AMP-004
Stage not disclosed · ActiveModality: biosimilar (interchangeable)
Aliases Insulin Aspart
Status note Interchangeable insulin product candidate; filing does not state whether this is the insulin candidate currently on file with the FDA.
AMP-005
Stage not disclosed · ActiveModality: biosimilar (interchangeable)
Aliases Recombinant Human Insulin
Status note Interchangeable insulin product candidate.
AMP-028
Stage not disclosed · ActiveModality: biosimilar
Status note Biosimilar outside the insulin portfolio; product identity not disclosed. API manufactured at the Eragny-sur-Epte, France facility.
BAQSIMI
Approved · ActiveModality: nasal powder
Aliases glucagon nasal powder
Indications
Severe hypoglycemia(Approved)
Status note Approved branded product acquired from Eli Lilly in June 2023; transition services completed January 1, 2025.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.